Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Baijin Life Science Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $9.22 Mil. Baijin Life Science Holdings's Total Assets for the quarter that ended in Mar. 2026 was $33.79 Mil.
Therefore, Baijin Life Science Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.27.
Baijin Life Science Holdings (OTCPK:MNNGF) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Baijin Life Science Holdings Liabilities-to-Assets Related Terms
Baijin Life Science Holdings Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings Liabilities-to-Assets Chart
For the Luxury Goods subindustry, Baijin Life Science Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baijin Life Science Holdings Liabilities-to-Assets vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Baijin Life Science Holdings's Liabilities-to-Assets falls into.
Baijin Life Science Holdings Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Baijin Life Science Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baijin Life Science Holdings (MNNGF) has a Liabilities-to-Assets of 0.27 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Baijin Life Science Holdings and its competitors.
Is Baijin Life Science Holdings' Liabilities-to-Assets too high?
Baijin Life Science Holdings' current Liabilities-to-Assets is 0.27. Overall, Baijin Life Science Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Liabilities-to-Assets compare to TPR?
Baijin Life Science Holdings' Liabilities-to-Assets of 0.27 can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Retail - Cyclical company?
A good Liabilities-to-Assets depends on the Retail - Cyclical industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Baijin Life Science Holdings and its competitors. Baijin Life Science Holdings's current Liabilities-to-Assets is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, Baijin Life Science Holdings (MNNGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.10 — trading 100% above its estimated fair value. The current Liabilities-to-Assets is 0.27. Baijin Life Science Holdings' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Liabilities-to-Assets is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?
Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued.
The current stock price of $0.10 is trading 100% above its estimated GF Value™ of $0.05.
GuruFocus considers Baijin Life Science Holdings to be Significantly Overvalued.
Key valuation signals for MNNGF:
Liabilities-to-Assets: 0.27
GF Value™: $0.05 vs. price of $0.10 (100% above fair value)
No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
26GF Score
Get the complete analysis for MNNGF
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNGF has been successfully added to your 
